Physician profile
Robert W Pollock
NPI 1538148572
$263,657.58
in general payments reported to CMS, 2019-2025
3 companies · $44K in 2025
The $44K reported for 2025 was more than what 95% of Clinical Pathology providers received nationally (typical 2025 total: $116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $48K · 2021: $50K · 2022: $28K · 2023: $17K · 2024: $35K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $94K · Travel and Lodging: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $94,166.86 |
| Travel and Lodging | $1,606.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $221,695.69 | 2020-2025 | |
| Shire North American Group INC | $41,946.62 | 2019 | |
| Rare Disease Therapeutics, INC. | $15.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.